Regeneron Pharmaceuticals (NQ:REGN)

735.20 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

66 67 Next >

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

June 20, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss ↗

June 18, 2025

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Via Stocktwits

Topics Death

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

June 15, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals ↗

May 30, 2025

Via Benzinga

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025 ↗

June 15, 2025

These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.

Via The Motley Fool

Topics Stocks

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

June 13, 2025

From 23andMe, Inc.

Via GlobeNewswire

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025 ↗

June 13, 2025

Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you.

Via The Motley Fool

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor? ↗

June 12, 2025

Via The Motley Fool

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies ↗

June 11, 2025

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.

Via Benzinga

Regeneron Pharma Shares Rise Over 3% After Key Signal ↗

June 10, 2025

A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.

Via Benzinga

Which S&P500 stocks are moving on Monday? ↗

June 09, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season ↗

June 09, 2025

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Via Benzinga

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

June 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗

June 05, 2025

MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.

Via Benzinga

23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer ↗

June 05, 2025

Regeneron previously won 23andMe at auction. But now the company wants to reopen bidding with an offer from its former CEO.

Via Investor's Business Daily

Topics Bankruptcy Lawsuit

Why Regeneron Is Falling And Why You Should Avoid It ↗

June 04, 2025

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Via Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

June 03, 2025

Via Benzinga

Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target ↗

June 02, 2025

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Via Benzinga

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response ↗

June 02, 2025

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Via Benzinga

Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500 ↗

June 02, 2025

Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the...

Via Stocktwits

Topics Death

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip ↗

June 02, 2025

Via The Motley Fool

Topics Economy

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

June 02, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

June 02, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN) ↗

June 02, 2025

US stocks ended May cautiously after strong monthly gains, as renewed trade tensions with China stirred market uncertainty.

Via Chartmill

Topics World Trade

Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? ↗

June 01, 2025

11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts.

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

May 31, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Top S&P500 movers in Friday's session ↗

May 30, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

May 30, 2025

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.